Velasof (Sofosbuvir Velpatasvir Tablet) 400MG 100MG

Velasof (sofosbuvir velpatasvir) is an antiviral medication used to treat chronic hepatitis C infections. This 400mg/100mg tablet combines two active ingredients for broad genotype coverage. Suitable for adults and children 6+, it supports sustained virologic response. Order online for discreet delivery.

Strength

400MG 100MG

Pack Size

28s

Storage

Ambient

Manufacturer / TM Owner

Hetero Labs Ltd

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Velasof is prescribed to treat chronic hepatitis C virus (HCV) infection in adults and children aged 6 and older. It combines sofosbuvir and velpatasvir to target multiple HCV genotypes. The medication helps reduce the amount of virus in the body. Patients often ask, 'what is Velasof used for' when considering treatment options.

Side Effects

Velasof works by interfering with the virus’s ability to replicate, helping the body clear the infection over time. Many users report improved energy levels and reduced symptoms like fatigue as treatment progresses. Some may experience mild digestive effects during the first few weeks. Effects vary by individual response to therapy.

Precautions & Warnings

Store Velasof at room temperature away from moisture and heat. Keep out of reach of children and pets. Inform your healthcare provider about all medications and supplements you’re taking before starting treatment. Avoid sharing this medication with others, even if they have similar symptoms.

Avoid Interactions

Velasof may interact with certain medications, including strong CYP inducers like rifampin or St. John’s wort. Antacids, H2 blockers, and proton pump inhibitors can reduce its effectiveness if taken simultaneously. Always consult a healthcare professional before combining with other drugs. Alcohol use may impact liver function during treatment.

References

Frequently Asked Questions

Velasof is used to treat chronic hepatitis C virus (HCV) infection in adults and children 6+.

Typical treatment duration is 12 weeks, but this may vary based on genotype and medical history.

Some medications may interact; consult a healthcare provider before combining with Velasof.

Mild side effects may include headache, fatigue, or nausea; report persistent issues to a doctor.

Safety during pregnancy has not been established; discuss risks with a healthcare provider.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.